Insiders Eli Lilly and Company

Stocks

LLY

US5324571083

Pharmaceuticals

Market Closed - NYSE Other stock markets 01:31:54 10/07/2026 am IST			Pre-market 04:47:44 pm
1,216.95 ^USD	+0.09%		1,232.21	+1.25%

09/07	South African regulators issue recall of Ozempic copies	RE
09/07	Alchemab Therapeutics Ltd announced that it has received £108.64704 million in funding from a group of investors	CI

Insiders

23/06	Trimtech Therapeutics Limited announced that it has received £35.6 million in funding from a group of investors	CI
12/06	Eli Lilly Insider Sold Shares Worth $2,876,925, According to a Recent SEC Filing	MT
10/06	Lilly's Weight Loss Sets High Bar for Obesity Drug Race	MT
28/05	Lilly Goes on $20B Buying Spree as It Seeks Next Act	MT
26/05	Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion	MT
26/05	Lilly's One-Time Cholesterol Shot	MT
26/05	Lilly Gets Back Into the Vaccine Business With New Deals	MT
30/04	Sun Pharma, Lilly Lead Latest Healthcare Deal Rush	MT
08/04	Incyclix Bio, LLC announced that it has received $46.25 million in funding from a group of investors	CI
02/04	Novo's New US Chief on Lilly's Rival Weight-Loss Pill	MT
24/02	Novo's stumbles burnish Lilly's widening lead in weight-loss drugs	RE
12/01	Juvena Therapeutics, Inc. announced that it has received $33.5 million in funding from Bison Ventures, Jefferson Life Sciences, Mubadala Capital, Manta Ray Ventures LLC, Eli Lilly and Company	CI
07/01	Mediar Therapeutics, Inc. announced that it has received $76 million in funding from Amplitude Ventures Inc., ICG America, Inc., Longwood Fund, Asahi Kasei Pharma America Corporation, Alexandria Real Estate Equities, Inc.	CI
08/12	Carolyn Bertozzi returns to Lilly board of directors	RE
01/12	Lilly Cuts Prices for Cash Buyers of Weight-Loss Drug Zepbound	MT
22/11	Eli Lilly & Co elects Carolyn R. Bertozzi to board - SEC filing	RE
22/11	Eli Lilly and Company Announces Appointment of Carolyn R. Bertozzi, Ph.D as New Board Member and Member of Science and Technology Committee and the Ethics and Compliance Committee, Effective December 8, 2025	CI
13/11	Gate Bioscience, Inc. announced that it has received $64.999995 million in funding from Forbion Capital Partners B.V., Eli Lilly and Company, Versant Venture Management, LLC, Andreessen Horowitz LLC, GV Management Company, LLC, Arch Venture Partners, L.P.	CI
07/11	Eli Lilly and Company Announces Management Appointments	CI
30/25/30	Cipla GCEO Vohra says co will take Eli Lilly's Yurpeak (Mounjaro) into Tier 2, Tier 3 markets with partnership	RE
09/25/09	Eli Lilly and Company Appoints Peter Marks as New Head of Infectious Disease and Senior VP of Molecule Discovery	CI
08/25/08	Eli Lilly says Peter Marks named senior VP of molecule discovery & head, infectious disease	RE
08/25/08	Eli Lilly taps former US FDA official Peter Marks to head infectious disease	RE
08/25/08	Ex-FDA regulator Peter Marks joins Eli Lilly - Stat News	RE
17/25/17	Lilly's GLP-1 Pill Outperforms Older Novo Drug	MT